Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape
Top Cited Papers
- 21 October 2012
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 18 (11) , 1688-1692
- https://doi.org/10.1038/nm.2985
Abstract
A minority of HIV-1–infected individuals develop broadly neutralizing antibodies, which are considered an important goal of many HIV vaccine strategies. Moore et al. now report their study of the evolution of a broadly neutralizing antibody response targeting a glycan on the viral envelope in two HIV-1–infected individuals. Their findings show that the targeted glycan is absent early in acute infection but develops over time as the virus escapes initial antibody-mediated pressure. Neutralizing antibodies are likely to play a crucial part in a preventative HIV-1 vaccine. Although efforts to elicit broadly cross-neutralizing (BCN) antibodies by vaccination have been unsuccessful1,2,3, a minority of individuals naturally develop these antibodies after many years of infection4,5,6,7. How such antibodies arise, and the role of viral evolution in shaping these responses, is unknown. Here we show, in two HIV-1–infected individuals who developed BCN antibodies targeting the glycan at Asn332 on the gp120 envelope, that this glycan was absent on the initial infecting virus. However, this BCN epitope evolved within 6 months, through immune escape from earlier strain-specific antibodies that resulted in a shift of a glycan to position 332. Both viruses that lacked the glycan at amino acid 332 were resistant to the Asn332-dependent BCN monoclonal antibody PGT128 (ref. 8), whereas escaped variants that acquired this glycan were sensitive. Analysis of large sequence and neutralization data sets showed the 332 glycan to be significantly under-represented in transmitted subtype C viruses compared to chronic viruses, with the absence of this glycan corresponding with resistance to PGT128. These findings highlight the dynamic interplay between early antibodies and viral escape in driving the evolution of conserved BCN antibody epitopes.This publication has 38 references indexed in Scilit:
- Rapid development of glycan-specific, broad, and potent anti–HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaqueProceedings of the National Academy of Sciences, 2011
- A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan ShieldScience, 2011
- Broad neutralization coverage of HIV by multiple highly potent antibodiesNature, 2011
- Epitopes Immediately below the Base of the V3 Loop of gp120 as Targets for the Initial Autologous Neutralizing Antibody Response in Two HIV-1 Subtype B-Infected IndividualsJournal of Virology, 2011
- The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4 + T Cell Decline and High Viral Load during Acute InfectionJournal of Virology, 2011
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in WomenScience, 2010
- Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1Virology, 2010
- Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine TargetScience, 2009
- Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection AlgorithmJournal of Virology, 2009
- Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C InfectionJournal of Virology, 2007